Nintedanib* is an angiokinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1–3, platelet-derived growth factor receptors (PDGFR) α and ß and fibroblast growth factor receptors (FGFR) 1–3.1 This page details nintedanib’s licensing and MoA.
Nintedanib (VARGATEF®) is approved in the EU and in other countries worldwide in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first-line chemotherapy.1
The role of angiogenesis in cancer
Angiogenesis plays a crucial role in the development of cancer, with tumor growth and metastatic spread dependent on it.2 Angiogenesis is stimulated when tissues or tumor cells require oxygen and nutrients, and is regulated by growth factors that bind to and activate growth factor receptor tyrosine kinases to drive downstream signaling.2–5 Angiokinase inhibitors may block components of the angiogenesis signaling pathway, and thus may limit tumor growth.4,6
There is also an increasing body of preclinical and clinical evidence to suggest that sustained angiogenesis can result in immunosuppression, which can facilitate immune evasion.7 Anti-angiogenic drugs may, therefore, help convert an immunosuppressive microenvironment to an immunosupportive microenvironment, as well as normalizing the tumor vasculature.7
Nintedanib’s mechanism of action
Nintedanib is a triple angiokinase inhibitor that simultaneously inhibits the kinase activity of VEGFRs 1–3, PDGFRs α and β, and FGFRs 1–3.1,8,9 In doing so, nintedanib blocks the following functions of its target kinases:
Intracellular signaling via these receptors is necessary for the proliferation and survival of endothelial cells and perivascular cells (pericytes and vascular smooth muscle cells).1 Nintedanib competitively binds to the adenosine triphosphate (ATP) binding pocket of these receptors in the cleft between the NH2- and the COOH-terminal lobes of the kinase domain.9 By binding to these receptors and blocking intracellular signaling, nintedanib hinders the formation of new tumor blood vessels, inhibits vessel maturation and disrupts the maintenance of vascular integrity, which may impact tumor growth.6,8,12
Nintedanib mechanism of action: triple angiokinase inhibition1,6,8–12
FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Preclinical studies have shown that nintedanib blocks VEGFR-2 activation for up to 32 hours, providing sustained inhibition of receptor activation.9 Preclinical data also show that nintedanib inhibits Akt and MAPK phosphorylation in endothelial and vascular smooth muscle cells and pericytes. It also induces rapid changes in tumor perfusion and permeability, as measured by DCE-MRI, in xenograft models of different tumor types. The antitumor activity of nintedanib was reported in a number of different tumor xenograft models, including a Calu-6 NSCLC model. In addition, the combination of nintedanib with docetaxel or pemetrexed has also been shown to increase antitumor activity in xenograft models.13
Nintedanib does not induce epithelial-to-mesenchymal transition (EMT) and does not induce an invasive phenotype in vitro;14 indeed, it has been shown to potentially reverse EMT in vitro.15
Nintedanib (VARGATEF®) summary of product characteristics, December 2019 (Accessed: June 2020).
de Mello RA, et al. Recent Pat Anticancer Drug Discov 2012;7(1):118-31.
Nishida N, et al. Vasc Health Risk Manag 2006;2(3):213-9.
Papetti M, et al. Am J Physiol Cell Physiol 2002;282(5):C947-70.
Hanahan D, et al. Cell 2011;144(5):646-74.
Carmeliet P, et al. Nature 2011;473(7347):298-307.
Popat S, et al. Lung Cancer 2020;144:76–84.
Rashdan S, et al. Expert Opin Pharmacother 2014;15(5):729–39.
Hilberg F, et al. Cancer Res 2008;68(12):4774–82.
Ferrara N, et al. Nat Med 2003;9(6):669–76.
Andrae J, et al. Genes Dev 2008;22(10):1276–312.
Ahmad I, et al. Biochim Biophys Acta 2012;1823(4):850–60.
Hilberg F, et al. J Thorac Oncol 2007;2(8):S380.
Kutluk Cenik B, et al. Mol Cancer Ther 2013;12(6):992–1001.
Huang RY, et al. Oncotarget 2015;6(26):22098–113.
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: August 2020
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue